In this podcast GU NURSES CONNECT members Brenda Martone and Jennifer Sutton discuss the nurse role in managing treatment intensification for metastatic castration sensitive prostate cancer(mCSPC) patients with triplet therapy of ADT + docetaxel + a novel hormonal agent (NHA). They focus on patient selection, AE management and drug-drug interactions. The experts discuss key data from the PEACE 1 and ARASENS trials of triplet therapy with abiraterone and darolutamide respectively, in combination with ADT and docetaxel. They discuss the importance of the nurse role in communicating and educating the patient about the benefits and risks of different triplet regimens. They debate whether triplet therapy should be the new standard of care for all mCSPC patients and discuss the patient subgroups that benefit the most from early treatment intensification.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related